Brief Title
Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Official Title
Randomized Phase I Study Combining Suppression of T Regulatory Cells With WT1 Vaccine Therapy for AML Patients in Complete Remission
Brief Summary
This randomized phase I trial studies the side effects and best way to give vaccine therapy
together with basiliximab in treating patients with acute myeloid leukemia (AML) in complete
remission. Vaccines made from the WT1 peptide may help the body build an effective immune
response to kill cancer cells. Montanide ISA 51 VG and poly-ICLC may enhance this response.
Monoclonal antibodies, such as basiliximab, can block cancer growth in different ways. Some
block the ability of cancer to grow and spread. Others find cancer cells and help kill them
or carry cancer-killing substances to them. It is not yet known whether WT1 126-134 peptide
vaccine with Montanide ISA 51 VG is more effective than with poly-ICLC when given together
with basiliximab in treating AML
Detailed Description
PRIMARY OBJECTIVES:
I. To examine the immunogenicity of WT1 peptide (WT1 126-134 peptide vaccine) emulsified in
Montanide (Montanide ISA 51 VG) in elderly patients with AML.
II. To determine whether toll-like receptor 3 (TLR3) agonist (poly-L-lysine and carboxymethyl
cellulose [poly ICLC]) could be a potent immunologic adjuvant, and increases the frequencies
of WT1-specific T cells following vaccination.
III. To determine whether depletion of regulatory T cells occurs upon administration of the
anti-cluster of differentiation (CD)25 monoclonal antibody Basiliximab, and whether this is
associated with increased frequencies of WT1-specific T cells following vaccination.
IV. To assess whether WT1 vaccination +/- TLR3 agonist (poly ICLC) combined with Basiliximab
results in decreased levels of WT1 transcripts in peripheral blood cells compared to WT1
vaccination +/- TLR3 as measured by quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR).
SECONDARY OBJECTIVES:
I. To examine the safety and gain preliminary information on efficacy of WT1 peptide
vaccination +/- TLR3 agonist (poly ICLC) combined with Basiliximab.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG
subcutaneously (SC) on day 0 and then once every 2 weeks.
ARM B: Patients receive WT1 126-134 peptide vaccine emulsified in poly-ICLC SC on day 0 and
then once every 2 weeks.
ARM C: Patients assigned to Arm C receive basiliximab intravenously (IV) over 30 minutes on
day -7 and WT1 126-134 peptide vaccine as in Arm A or Arm B, whichever had a superior
cellular immune response.
In all arms, treatment continues for 12 weeks in the absence of disease progression or
unacceptable toxicity. Patients may then receive 6 additional monthly vaccinations.
After completion of study treatment, patients are followed up for up to 2 years.
Study Phase
Phase 1
Study Type
Interventional
Primary Outcome
Comparison of peptide specific immunologic response between regimens
Secondary Outcome
Molecular response in terms of WT1 expression
Condition
Adult Acute Myeloid Leukemia in Remission
Intervention
basiliximab
Study Arms / Comparison Groups
Arm A (vaccine with Montanide)
Description: Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 0 and then once every 2 weeks.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Biological
Estimated Enrollment
7
Start Date
December 5, 2011
Completion Date
March 2018
Primary Completion Date
February 2, 2015
Eligibility Criteria
Inclusion Criteria:
- Patients with Hematological malignancies, including AML, MDS, CML in blast phase and
other conditions at the investigator's discretion.
- Bone marrow biopsy-confirmed CR or CRi, more than CR1 is allowed, such as CR2 or CR3.
The enrollee is deemed not a candidate for stem cell transplant due to advanced age or
co-morbidities; or the enrollee does not have donor available; or enrollee refuses
stem cell transplant due to personal belief; or stem cell transplant is not current
standard of care. Patients who are post stem cell transplant in CR or CRi are allowed
if they are off immunosuppression,and not treated with systematic steroid for GVHD
- Karnofsky performance status index > or = 80%
- Written informed consent
- Absolute neutrophil count > or = 500/μl
- Platelet count >= 20,000/μl with transfusion
- Creatinine = or < 2 x upper limit of normal (ULN)
- Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate
transaminase (SGPT) = or < 5 x ULN
- Bilirubin = or < 3 x ULN
- Human leukocyte antigens (HLA) typing: patient must express HLA-A2
- Age > 18 years and < 85 years
- Electrocardiogram (EKG) without evidence of arrhythmia or changes that indicate acute
ischemia
- Pulse oximetry showing oxygen saturation of at least 90% on room air
- No irreversible coagulopathy, international normalized ratio (INR) =< 2
- No sign of tumor lysis syndrome, uric acid needs to be in normal range prior to
treatment
- Not in diabetic ketoacidosis (DKA), sickle cell crisis, and not having severe
peripheral vascular disease on active anti-coagulation treatment
Exclusion Criteria:
- Pregnant or nursing women; women who still have child-bearing potential must be tested
for urinary or serum beta human chorionic gonadotropin (βHCG)
- Biological or chemotherapy in the 4 weeks prior to the start of dosing
- Patients with intrinsic immunosuppression, including seropositivity for human
immunodeficiency virus (HIV) antibody; patients should be tested for HIV
- Serious concurrent infection, including active tuberculosis, hepatitis B, or hepatitis
C; patients should be tested for hepatitis B surface antigen and hepatitis C antibody;
patients who are hepatitis C antibody (Ab) positive can be eligible if they are PCR
negative
- Active or history of confirmed autoimmune disease
- Concurrent systemic corticosteroids (except physiologic replacement doses) or other
immunosuppressive drugs (eg. cyclosporin A)
- Active or history of autoimmune disease including but not limited to rheumatoid
arthritis (rheumatoid factor [RF]-positive with current or recent flare), inflammatory
bowel disease, systemic lupus erythematosus (clinical evidence with antinuclear
antibody [ANA] 1:80 or greater), ankylosing spondylitis, scleroderma, multiple
sclerosis, autoimmune hemolytic anemia, and immune thrombocytopenic purpura;
seropositivity alone will not be considered positive
- Psychiatric illness that may make compliance to the clinical protocol unmanageable or
may compromise the ability of the patient to give informed consent; patients with
clinical evidence of dementia should have a competent designee participate in decision
Gender
All
Ages
18 Years - 85 Years
Accepts Healthy Volunteers
No
Contacts
Hongtao Liu, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01842139
Organization ID
11-0545
Secondary IDs
NCI-2011-03588
Responsible Party
Sponsor
Study Sponsor
University of Chicago
Collaborators
National Cancer Institute (NCI)
Study Sponsor
Hongtao Liu, Principal Investigator, University of Chicago
Verification Date
March 2018